日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

NAFLD Associates with Sarcopenia Defined by Muscle Mass and Slow Walking Speed: A Cross-Sectional Analysis from the Framingham Heart Study

非酒精性脂肪性肝病与肌肉量减少和步行速度减慢所定义的肌少症相关:来自弗雷明汉心脏研究的横断面分析

Altajar, Sarah; Wang, Na; Rosenthaler, Max P; Murabito, Joanne M; Long, Michelle T

Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota

结合基因组学和流行病学数据,比较SARS-CoV-2 Alpha和Iota变种的传播能力

Petrone, Mary E; Rothman, Jessica E; Breban, Mallery I; Ott, Isabel M; Russell, Alexis; Lasek-Nesselquist, Erica; Badr, Hamada; Kelly, Kevin; Omerza, Greg; Renzette, Nicholas; Watkins, Anne E; Kalinich, Chaney C; Alpert, Tara; Brito, Anderson F; Earnest, Rebecca; Tikhonova, Irina R; Castaldi, Christopher; Kelly, John P; Shudt, Matthew; Plitnick, Jonathan; Schneider, Erasmus; Murphy, Steven; Neal, Caleb; Laszlo, Eva; Altajar, Ahmad; Pearson, Claire; Muyombwe, Anthony; Downing, Randy; Razeq, Jafar; Niccolai, Linda; Wilson, Madeline S; Anderson, Margaret L; Wang, Jianhui; Liu, Chen; Hui, Pei; Mane, Shrikant; Taylor, Bradford P; Hanage, William P; Landry, Marie L; Peaper, David R; Bilguvar, Kaya; Fauver, Joseph R; Vogels, Chantal B F; Gardner, Lauren M; Pitzer, Virginia E; St George, Kirsten; Adams, Mark D; Grubaugh, Nathan D

Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease

骨骼肌功能障碍在非酒精性脂肪肝疾病的发生发展中的作用

Altajar, Sarah; Baffy, Gyorgy

Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb

英夫利昔单抗-Dyyb生物类似药推广计划的流程和临床结果

Bhat, Shubha; Altajar, Sarah; Shankar, Divya; Zahorian, Toni; Robert, Regine; Qazi, Taha; Shah, Bhavesh; Farraye, Francis A

Trends in total ankle arthroplasty and revisions in the Medicare database

Medicare数据库中全踝关节置换术和翻修术的趋势

Law, Tsun Yee; Sabeh, Karim G; Rosas, Samuel; Hubbard, Zachary; Altajar, Sarah; Roche, Martin W